Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
Executive Summary
FDA 'complete response' letter follows advisory committee's conclusion that the current naloxone approval standard is inadequate.
You may also be interested in...
Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue
Harm Reduction Therapeutics, which has sought funding for a US Rx-to-OTC new drug application, receives grant from Purdue Pharma that enables filing and launching the product in a targeted 100,000 retail locations within two years.
Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue
Harm Reduction Therapeutics, which has sought funding for a US Rx-to-OTC new drug application, receives grant from Purdue Pharma that enables filing and launching the product in a targeted 100,000 retail locations within two years.
Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
Nonprofit Harm Reduction Therapeutics targets an OTC switch of naloxone, an opioid antagonist used to reverse an opioid overdose. It aims to make the product available at low cost in 110,000 retail locations nationwide.